Fig. 3From: Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trialPatients achieving (A) ≥ 50% and (B) ≥ 75% reduction in monthly migraine days (efficacy analysis set). †n/N = 2/144; ‡n/N = 5/146. Epti, eptinezumabBack to article page